1. Urinary β-2 Microglobulin Levels Sensitively Altered in an Osteomalacia Patient Receiving Add-on Adefovir Dipivoxil Therapy for Hepatitis B Virus Infection
- Author
-
Kiyoaki Ito, Junko Takagi, Takkan Morishima, Tatsuo Ito, Masashi Yoneda, Tomohiko Ohashi, Hiroyuki Morita, Sho Hirase, and Kazuo Otake
- Subjects
medicine.medical_specialty ,Side effect ,viruses ,Urinary system ,Organophosphonates ,medicine.disease_cause ,Antiviral Agents ,Gastroenterology ,03 medical and health sciences ,Hepatitis B, Chronic ,0302 clinical medicine ,Japan ,Internal medicine ,Internal Medicine ,Adefovir ,Humans ,Medicine ,Aged ,Hepatitis B virus ,Osteomalacia ,business.industry ,Beta-2 microglobulin ,Adenine ,virus diseases ,General Medicine ,Hepatitis B ,medicine.disease ,Virology ,030220 oncology & carcinogenesis ,Alkaline phosphatase ,Female ,030211 gastroenterology & hepatology ,beta 2-Microglobulin ,business ,medicine.drug - Abstract
Adefovir dipivoxil (ADV) is effective for hepatitis B virus (HBV) infection; however, ADV may provoke renal injury resulting in osteomalacia, and this side effect is seldom recognized until bone fractures emerge. We herein present a 66-year-old woman with HBV infection who received ADV for 6 years. Although she exhibited no sign of bone fractures, her urinary β-2 microglobulin (β2MG) level increased to 83,837 μg/L and scintigraphy revealed minimal fractures of the third rib. ADV was subsequently reduced and her urinary β2MG rapidly fell to 3,637 μg/L. Conversely, her urinary N-acetyl-β-D-glucosaminidase, and serum phosphate, alkaline phosphatase levels did not respond.
- Published
- 2016